Management Comment "In 2015, committed we build a in-house U.S. manufacturing capabilities, which we believe is strategically important. The company leased an additional 27,000 feet at its current location and we conceded the design phase of project. The facility is designed to support the efficient manufacturing of our novel cellular immunotherapies for clinical trials and early commercial requirements."
-Tom Farrell CEO